Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
Marvel Biosciences Corp. announces it has identified two lead pediatric-friendly liquid formulations of its patented lead compound, MB-204.
-
Unyte Health acquires Vital Links and Vital Sounds, enhancing its suite of powerful listening therapies for clinicians and healthcare providers.
-
Marvel announces financial and strategic backing from 5 Horizons Ventures to support its upcoming Phase 1 clinical trial of patented lead asset MB-204
-
Lighthouse Autism Center is Opening in Rocky Mount, North Carolina in June 2026
-
Marvel Biosciences secures $600,000 in non-dilutive funding from Alberta Innovates to support Phase I clinical trials of its autism-focused patented MB-204
-
Lighthouse Autism Center is Opening in Asheboro, North Carolina this August
-
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204, lead asset discovery, a patented neuroactive adenosine A2A antagonist
-
Peer-reviewed publication validates the potential of Itay&Beyond's human CNS platform for advanced disease stratification, translational research, and R&D
-
New York, March 05, 2026 (GLOBE NEWSWIRE) -- The Brain & Behavior Research Foundation (BBRF) invites the public to a free webinar, “Helping Children With Autism Tune Into Voices” on Tuesday,...
-
MCLEAN, Va., March 04, 2026 (GLOBE NEWSWIRE) -- The Thought Leadership & Innovation Foundation (TLI) is proud to announce its adoption of the Higher Logic platform to power community engagement...